Rheumatology and Therapy, 2023 Introduction This post hoc analysis of the phase 3 rheumatoid arthritis (RA) filgotinib clinical trial program assessed the effect of filgotinib on body mass index (BMI) in patients with RA and the impact of BMI on the efficacy and safety of filgotinib ...
Alejandro Balsa +2 more
exaly +7 more sources
Comparison of the Efficacy of Different Doses of Filgotinib in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on the RCTs [PDF]
Dose-ResponseObjective This study compared the efficacy of different doses of filgotinib (100 mg vs 200 mg) in the treatment of rheumatoid arthritis (RA). Methods We conducted a systematic review of 4 electronic databases up to January 2025.
Xia Ye +7 more
doaj +2 more sources
A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib. [PDF]
PLoS ONEBackgroundAlthough filgotinib, a selective Janus kinase 1 inhibitor, has been increasingly applied in the treatment of inflammatory diseases, its comprehensive safety profile remains insufficiently characterized.
Yinli Shi +7 more
doaj +2 more sources
Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team [PDF]
Intestinal ResearchJanus kinase (JAK) inhibitors are an important treatment option for ulcerative colitis, providing rapid onset of action, oral administration, and efficacy even after biologic failure. The 3 approved agents—tofacitinib, filgotinib, and upadacitinib—differ
Seung Min Hong +20 more
doaj +2 more sources
Rheumatology and Therapy, 2020 Introduction The Janus kinase (JAK) inhibitor therapeutic class has shown significant clinical benefit in the treatment of rheumatoid arthritis (RA).
Peter C Taylor
exaly +2 more sources
Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis – report of two filgotinib-treated cases and literature review [PDF]
Acta OncologicaBackground and purpose: Treatment of cancer with immune checkpoint inhibitors (ICIs) entails a risk of immune-related adverse events (irAEs). Data on the treatment of immune-related enterocolitis (irEC) in patients with inadequate symptom control after ...
Henrik Ekedahl +5 more
doaj +2 more sources
Rheumatoid Arthritis Preceded by Interstitial Lung Disease Controlled by Long‐Term Treatment With the Janus Kinase 1‐Selective Inhibitor, Filgotinib: A Case Report [PDF]
Respirology Case ReportsWe present a case of active interstitial lung disease (ILD) preceding the onset of rheumatoid arthritis (RA). A 68‐year‐old man had dyspnea, decreased forced vital capacity, and elevated Krebs von den Lungen‐6 levels.
Takeo Sato +4 more
doaj +2 more sources
Clinical and Experimental Gastroenterology, 2022 Arianna Dal Buono,1 Roberto Gabbiadini,1 Virginia Solitano,1,2 Edoardo Vespa,1,2 Tommaso Lorenzo Parigi,1,2 Alessandro Repici,2,3 Antonino Spinelli,1,2,4 Alessandro Armuzzi1,2 1IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy ...
Arianna Dal Buono +2 more
exaly +2 more sources
Immune‐Mediated Thrombocytopenia in an Ulcerative Colitis Patient After Initiating Filgotinib Treatment: A Case Report [PDF]
Clinical Case ReportsModerate‐to‐severe ulcerative colitis can be effectively treated with JAK‐1 inhibition, but platelet counts should be closely monitored, especially in active disease.
M. J. van derHoff +2 more
doaj +2 more sources
Rationale, Design and Methods of the Filgotinib Initial Response Study in Rheumatoid Arthritis (FIRST-RA) [PDF]
Rheumatology and TherapyIntroduction Filgotinib is an oral Janus kinase 1 (JAK1) preferential inhibitor approved for adult patients with moderate-to-severe active rheumatoid arthritis (RA) who have responded inadequately to, or who are intolerant of, one or more disease ...
Georg Pongratz +6 more
doaj +2 more sources